CE
$65.57
+4.01
(+6.51%)
As of Oct 22, 2026, 9:29 PM EDT · cached
Price history
Celcuity Inc (CELC) is trading up at $65.57 (+6.51%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: September 20, 2017 · $9.50 offering · NASDAQ · View IPO details →
Celcuity Inc net income history (FY2016–FY2025)
Net income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$3.33M | −$5.95M | −$7.93M | −$7.81M | −$9.56M | −$28.4M | −$39.4M | −$66.2M | −$113.3M | −$172.2M |
| Net income | −$3.31M | −$6.25M | −$7.48M | −$7.36M | −$9.47M | −$29.6M | −$40.4M | −$63.8M | −$111.8M | −$177.0M |
| EPS (diluted) | −$0.52 | −$0.84 | −$0.74 | −$0.72 | −$0.92 | −$2.21 | −$2.64 | −$2.69 | −$2.83 | −$3.79 |
| Balance sheet | ||||||||||
| Cash and equivalents | $5.86M | $2.69M | $15.9M | $18.7M | $11.6M | $84.3M | $24.6M | $30.7M | $22.5M | $165.7M |
| Total assets | $6.06M | $32.0M | $26.0M | $20.3M | $13.0M | $85.9M | $175.7M | $191.2M | $245.1M | $466.6M |
| Total liabilities | $445.4K | $578.1K | $682.2K | $983.2K | $1.25M | $17.2M | $41.9M | $51.5M | $129.5M | $366.0M |
| Long-term debt | — | — | — | — | — | $16.0M | $35.8M | $37.6M | $105.1M | $137.5M |
| Shareholders' equity | $5.61M | $31.4M | $25.3M | $19.3M | $11.7M | $68.7M | $133.8M | $139.8M | $115.6M | $100.6M |
| Cash flow | ||||||||||
| Operating cash flow | −$2.89M | −$4.95M | −$6.08M | −$6.00M | −$7.15M | −$20.3M | −$36.0M | −$53.8M | −$83.5M | −$153.3M |
| Capital expenditure | $40.9K | $239.8K | $629.6K | −$380.2K | $89.4K | $81.9K | $158.8K | $97.6K | $250.0K | $249.0K |
| Free cash flow | −$2.93M | −$5.19M | −$6.71M | −$5.62M | −$7.24M | −$20.4M | −$36.2M | −$53.9M | −$83.7M | −$153.5M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$30.1M | −$36.4M | −$36.1M | −$44.0M | −$42.8M | −$49.2M | −$50.5M | −$66.1M |
| Net income | −$29.8M | −$36.7M | −$37.0M | −$45.3M | −$43.8M | −$51.0M | −$52.8M | −$78.9M |
| EPS (diluted) | −$0.70 | −$0.87 | −$0.86 | −$1.04 | −$0.92 | −$0.97 | −$0.97 | −$1.44 |
| Balance sheet | ||||||||
| Cash and equivalents | $12.6M | $22.5M | $16.5M | $46.4M | $74.3M | $165.7M | $145.2M | $182.0M |
| Total assets | $273.0M | $245.1M | $218.1M | $183.6M | $476.0M | $466.6M | $410.2M | $828.2M |
| Total liabilities | $123.3M | $129.5M | $131.5M | $139.2M | $359.0M | $366.0M | $356.6M | $841.0M |
| Long-term debt | $104.8M | $105.1M | $105.3M | $105.6M | $137.2M | $137.5M | $137.9M | $0 |
| Shareholders' equity | $149.7M | $115.6M | $86.7M | $44.4M | $117.0M | $100.6M | $53.5M | −$12.8M |
| Cash flow | ||||||||
| Operating cash flow | −$20.6M | −$27.8M | −$35.9M | −$36.2M | −$44.8M | −$36.4M | −$55.1M | −$55.4M |
| Capital expenditure | $51.0K | $45.0K | $60.0K | $39.0K | $97.0K | $53.0K | $249.0K | $51.0K |
| Free cash flow | −$20.6M | −$27.8M | −$35.9M | −$36.3M | −$44.9M | −$36.5M | −$55.3M | −$55.5M |
From Celcuity Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Celcuity Inc
- Headquarters
- Minneapolis, Minnesota From SEC filings, Oct 2026
Recent News (3)
-
how InvestingPro’s Fair Value flagged Celcuity’s 52% decline
how InvestingPro’s Fair Value flagged Celcuity’s 52% decline
-
Celcuity at citigroup’s biopharma back to school summit: launch begins
Celcuity at citigroup’s biopharma back to school summit: launch begins
-
Celcuity at Wells Fargo healthcare conference: launch, data in focus
Celcuity at Wells Fargo healthcare conference: launch, data in focus
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International